CRISPR Therapeutics CFO granted 16,500 options at $67.74

CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer.

Accepted by SEC EDGAR 10/03/2025 - 05:36 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer. The filing discloses a stock option grant covering 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025. The option vests in 48 equal monthly installments beginning November 3, 2025 and carries an expiration date of October 3, 2035. The reporting person holds 16,500 derivative securities directly following the transaction.

Insider Trade Summary

Grant/Award: 16,500 shares

Grant/Award 1 txn

Insider Prasad Raju

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,500 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 16,500 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRSP disclose in this Form 4?

A stock option grant to the CFO for 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025.

What is the vesting schedule of the CRSP CFO’s option?

It vests in 48 equal monthly installments, starting on November 3, 2025.

When does the CRSP CFO option expire?

The option expires on October 3, 2035.

How many derivative securities are held after the transaction?

The reporting person holds 16,500 derivative securities directly after the transaction.

What is the exercise price of the option reported by CRSP?

The exercise price is $67.74 per share.

Who is the reporting person’s role at CRSP?

The reporting person is the Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$67.74	10/03/2025		A		16,500		(1)	10/03/2035	Common Shares	16,500	$0.00	16,500	D

Explanation of Responses:

1. This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.